[go: up one dir, main page]

EA201790601A1 - TREATMENT OF PROGRESSIVE ASSIFIED FIBRODISPLASIA - Google Patents

TREATMENT OF PROGRESSIVE ASSIFIED FIBRODISPLASIA

Info

Publication number
EA201790601A1
EA201790601A1 EA201790601A EA201790601A EA201790601A1 EA 201790601 A1 EA201790601 A1 EA 201790601A1 EA 201790601 A EA201790601 A EA 201790601A EA 201790601 A EA201790601 A EA 201790601A EA 201790601 A1 EA201790601 A1 EA 201790601A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
acvr2a
acvr1
acvr2b
progressive
Prior art date
Application number
EA201790601A
Other languages
Russian (ru)
Other versions
EA039118B1 (en
Inventor
Сара Дж. Хэтсел
Арис Н. Экономидис
Винсент Дж. Айдан
Original Assignee
Ридженерон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ридженерон Фармасьютикалз, Инк. filed Critical Ридженерон Фармасьютикалз, Инк.
Priority claimed from PCT/US2015/000100 external-priority patent/WO2016039796A2/en
Publication of EA201790601A1 publication Critical patent/EA201790601A1/en
Publication of EA039118B1 publication Critical patent/EA039118B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Приводятся способы лечения прогрессирующей оссифицирующей фибродисплазии (FOP). К таким способам относится применение в отношении субъекта с FOP эффективной схемы введения антагониста рецептора активина типа 2А (ACVR2A), и/или антагониста рецептора активина типа 2В (ACVR2B), и/или антагониста рецептора активина типа 1 (ACVR1). К таким антагонистам относятся слитые белки, содержащие один или более внеклеточных доменов (ECD) ACVR2A, ACVR2B и/или ACVR1 и домен Fc тяжелой цепи иммуноглобулина, а также антитела к ACVR2A, ACVR2B, ACVR1 или активину А.Methods for the treatment of progressive ossifying fibrodysplasia (FOP) are presented. Such methods include the use of an effective scheme for activin type 2A receptor antagonist (ACVR2A) and / or activin type 2B receptor antagonist (ACVR2B) and / or activin type 1 receptor antagonist (ACVR1) for a subject with FOP. These antagonists include fusion proteins containing one or more extracellular domains (ECD) of ACVR2A, ACVR2B and / or ACVR1 and the Fc domain of the immunoglobulin heavy chain, as well as antibodies to ACVR2A, ACVR2B, ACVR1 or activin A.

EA201790601A 2015-04-01 2015-09-14 Method for treating fibrodysplasia ossificans progressiva EA039118B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562141775P 2015-04-01 2015-04-01
PCT/US2015/000100 WO2016039796A2 (en) 2014-09-12 2015-09-14 Treatment of fibrodysplasia ossificans progressiva

Publications (2)

Publication Number Publication Date
EA201790601A1 true EA201790601A1 (en) 2017-07-31
EA039118B1 EA039118B1 (en) 2021-12-07

Family

ID=58385407

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790601A EA039118B1 (en) 2015-04-01 2015-09-14 Method for treating fibrodysplasia ossificans progressiva

Country Status (1)

Country Link
EA (1) EA039118B1 (en)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8859752B2 (en) * 2006-04-18 2014-10-14 The Trustees Of The University Of Pennsylvania SIRNA-based therapy of Fibrodyplasia Ossificans Progressiva (FOP)
CL2007002567A1 (en) * 2006-09-08 2008-02-01 Amgen Inc ISOLATED PROTEINS FROM LINK TO ACTIVINE TO HUMAN.
TW202021980A (en) * 2007-02-02 2020-06-16 美商艾瑟勒朗法瑪公司 Variants derived from actriib and uses therefor
US8507501B2 (en) * 2008-03-13 2013-08-13 The Brigham And Women's Hospital, Inc. Inhibitors of the BMP signaling pathway
WO2013063536A1 (en) * 2011-10-27 2013-05-02 Acceleron Pharma, Inc. Actriib binding agents and uses thereof
WO2013074557A1 (en) * 2011-11-14 2013-05-23 Regeneron Pharmaceuticals, Inc. Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and/or activin a
TWI655207B (en) * 2013-07-30 2019-04-01 再生元醫藥公司 Anti-activin A antibody and use thereof
JP6601687B2 (en) * 2014-03-31 2019-11-06 大日本住友製薬株式会社 Preventive and therapeutic agent for progressive ossification fibrodysplasia

Also Published As

Publication number Publication date
EA039118B1 (en) 2021-12-07

Similar Documents

Publication Publication Date Title
CY1122188T1 (en) THERAPEUTIC TREATMENT OF FIBRODYSPLASIA OSTEOPIUS PROGRESSIVE
CY1122216T1 (en) NEW HETERODIMER PROTEINS
EA201891992A1 (en) CHIMERIC RECEPTORS AND WAYS OF THEIR APPLICATION
MX2024006564A (en) PRO/LATENT ANTI-MYOSTATIN ANTIBODIES AND METHOD OF USE THEREOF.
MX2021013681A (en) Lag-3-binding molecules and methods of use thereof.
EA202190609A1 (en) ANTIBODIES AGAINST HLA-G, COMPOSITIONS CONTAINING ANTIBODIES AGAINST HLA-G, AND METHODS OF APPLICATION ANTIBODIES AGAINST HLA-G
EA201791093A1 (en) ANTIBODIES TO CD47, METHODS AND USE
CR20180225A (en) ANTI-TIGIT ANTIBODY AND METHODS OF USE
EA201692458A1 (en) ANTI-GITR ANTIBODIES AND METHODS OF THEIR APPLICATION
PE20240111A1 (en) BINDING MOLECULES TO PD-1 AND METHODS OF USE THEREOF
EA201790247A1 (en) PLATFORM FOR CLEANING BISPECIFIC ANTIBODIES
MX2017007491A (en) Blood brain barrier receptor antibodies and methods of use.
PE20160690A1 (en) HUMANIZED ANTI-CD134 (OX40) ANTIBODIES AND USES OF THEM
EA201792589A1 (en) ANTIBODIES AGAINST CD123 AND CONJUGATES OF INDICATED ANTIBODIES
AR093788A1 (en) IMMUNOTHERAPY WITH LINK AGENTS
EA201891732A1 (en) BISPECIFIC BINDING PROTEINS FOR PD-L1 AND KDR
EA201892440A1 (en) ANTIBODIES TO TL1A AND THEIR APPLICATIONS
PH12016501366A1 (en) Novel anti-baff antibodies
EA201991600A1 (en) COMPOUNDS MODULATING THE Aryl Hydrocarbon Receptor (AhR)
EA201890082A1 (en) EPITOPE ANTIBODIES
EA201991511A1 (en) GREMLIN-1 CRYSTAL STRUCTURE AND AN INHIBITING ANTIBODY
EA201791691A1 (en) SINGLE-DOMAIN ANTIBODIES DIRECTED TO CD1d
EA201992206A1 (en) MONOCLONAL ANTIBODY TO PD-L1
EA201690032A1 (en) ANTIBODIES TO LECTIN-LIKE RECEPTOR 1 OF OXIDATED LOW DENSITY LIPOPROTEINS AND METHODS OF APPLICATION
EA201790314A1 (en) NEW ANTIBODIES DIRECTED TO FC-GAMMA-RECEPTOR IIB AND FC-EPSILON-RECEPTOR